| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
Form 4: Mottola Frank, SVP, Chief Tech. Ops. Officer
Acquired 30,099 shares (Other Transaction) · Acquired 245,643 Employee Stock Option (right to buy) (Other Transaction) · Acquired 186,888 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 4: Horich William Todd, SVP, Chief Commercial Officer
Acquired 216,381 Employee Stock Option (right to buy) (Other Transaction) · Acquired 190,391 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 4: Dec Timothy C, SVP, Chief Financial Officer
Acquired 14,059 shares (Other Transaction) · Acquired 396,574 Employee Stock Option (right to buy) (Other Transaction) · Acquired 141,878 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 4: Barlow Carrolee, Director
Acquired 41,652 shares (Other Transaction) · Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 112,384 Director Stock Option (right to buy) (Other Transaction) |
| 04 Nov 2026 |
Form 4: Bhatt Padmanabh P., SVP of IP, CSO
Acquired 28,702 shares (Other Transaction) · Acquired 82,394 Employee Stock Option (right to buy) (Other Transaction) · Acquired 183,999 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 4: Sensenig Bethany, Director
Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 68,807 Director Stock Option (right to buy) (Other Transaction) |
| 04 Nov 2026 |
Form 4: Gemayel Georges, Director
Acquired 42,009 shares (Other Transaction) · Acquired 4,603 Restricted Stock Units (Other Transaction) · Acquired 119,215 Director Stock Option (right to buy) (Other Transaction) |
| 04 Nov 2026 |
Form 4: Khattar Jack A., Director
Acquired 3,413,555 shares (Other Transaction) · Acquired 3,937,295 Employee Stock Option (right to buy) (Other Transaction) · Acquired 1,221,960 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 4: Rubin Jonathan, SVP, Chief Medical Officer
Acquired 21,529 shares (Other Transaction) · Acquired 221,002 Employee Stock Option (right to buy) (Other Transaction) · Acquired 135,333 Restricted Stock Units (Other Transaction) |
| 04 Nov 2026 |
Form 3: Gemayel Georges, Director
No securities owned |
| 04 Nov 2026 |
Form 3: Sensenig Bethany, Director
No securities owned |
| 04 Nov 2026 |
Form 3: Khattar Jack A., Director
No securities owned |
| 04 Nov 2026 |
Form 3: Rubin Jonathan, SVP, Chief Medical Officer
No securities owned |
| 04 Nov 2026 |
Form 3: Horich William Todd, SVP, Chief Commercial Officer
No securities owned |
| 04 Nov 2026 |
Form 3: Mottola Frank, SVP, Chief Tech. Ops. Officer
No securities owned |
| 04 Nov 2026 |
Form 3: Dec Timothy C, SVP, Chief Financial Officer
No securities owned |
| 04 Nov 2026 |
Form 3: Bhatt Padmanabh P., SVP, Chief Scientific Officer
No securities owned |
| 04 Nov 2026 |
Form 3: Barlow Carrolee, Director
No securities owned |
| 03 Nov 2026 |
8-K: Other Events
Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “Indenture”), go... |
| 02 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
Anti-Corruption Laws, Anti-Money Laundering Laws, Export Controls and Sanctions |
Loading...